TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17110262
Drug: Light force
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Light force (25 g)
Study: 17110262
Drug: Heavy force
Normalized name: heavy mineral oil
DrugBank: Mineral oil (DB11057)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heavy force (225 g)
Study: 11040889
Drug: Out-patient treatment
Normalized name: Cough Out
DrugBank: Guaifenesin (DB00874)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Out-patient treatment
Study: 8936350
Drug: Acyclovir (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acyclovir (800 mg orally three times daily for 2 years)
Study: 8936350
Drug: Placebo (three
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (three times daily for 2 years)
Study: 3887100
Drug: Bendroflumethiazide (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bendroflumethiazide (5 mg/d)
Study: 15557943
Drug: Sedation with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sedation with midazolam and placebo pharyngeal spray (midazolam group)
Study: 15557943
Drug: Placebo sedation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo sedation and lidocaine pharyngeal spray (lidocaine group)
Study: 15557943
Drug: Placebo sedation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo sedation and placebo pharyngeal spray (placebo group)
Study: 15557943
Drug: No intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: No intravenous cannula/pharyngeal spray (control group)
Study: 9275135
Drug: Nebulized ipratropium
Normalized name: Ipratropium
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nebulized ipratropium (0.5 mg) plus salbutamol (2.5 mg) (Combivent)
Study: 9275135
Drug: Nebulized salbutamol
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nebulized salbutamol (2.5 mg) alone
Study: 7878598
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of lithium (1.68 mg)
Study: 7878598
Drug: Repetitive doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repetitive doses of lithium (0.56 mg twice a day for 11 days)
Study: 3067180
Drug: Topically applied
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topically applied tretinoin ophthalmic ointment (0.01%)
Study: 4594581
Drug: 100 to
Normalized name: Zionodil 100 Topical Lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 to 1,000 mug GHRIH administered by constant infusion over 75 minutes
Study: 4594581
Drug: 25 mug
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mug GHRIH administered by constant infusion
Study: 4594581
Drug: 10 mug
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mug GHRIH administered by constant infusion
Study: 4594581
Drug: 500 mug
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mug GHRIH injected by intravenous, subcutaneous, and intramuscular routes
Study: 4594581
Drug: 500 mug
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mug GHRIH injected intramuscularly in 2 ml of 16% gelatin
Study: 4594581
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg GHRIH in 1 ml of arachis oil
Study: 4594581
Drug: 1,000 mug
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,000 mug GHRIH during oral 50-g glucose tolerance test
Study: 4594581
Drug: Saline during
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline during oral 50-g glucose tolerance test
Study: 28578592
Drug: Adjunctive minocycline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive minocycline (200 mg/day)
Study: 23828329
Drug: Herbal supplement
Normalized name: LYDIA PINKHAM Herbal Supplement Liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Herbal supplement composed of Curcuma longa and Boswellia serrata
Study: 11349008
Drug: Genotype CC
Normalized name: dengue virus live antigen, CYD serotype 1 / dengue virus live antigen, CYD serotype 2 / dengue virus live antigen, CYD serotype 3 / dengue virus live antigen, CYD serotype 4 Injection [Dengvaxia]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genotype CC
Study: 7924451
Drug: Oxiconazole nitrate
Normalized name: Oxiconazole Nitrate
DrugBank: Oxiconazole (DB00239)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxiconazole nitrate lotion, 1 percent, used once or twice daily
Study: 20578385
Drug: Control therapy
Normalized name: Benzoyl Peroxide;Salicylic Acid;Vitamin E 8%; 2%; 5% Topical application Kit [INOVA 8/2 ACNE CONTROL THERAPY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control therapy (acupuncture or other therapy on the upper extremities)
Study: 18251359
Drug: Triptorelin (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triptorelin (0.2 mg)
Study: 14614665
Drug: Atovaquone and
Normalized name: Atovaquone and proguanil only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atovaquone and proguanil (20 and 8 mg/kg of body weight, respectively, administered once daily for 3 days)
Study: 14614665
Drug: Amodiaquine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amodiaquine (10 mg/kg of body weight, once daily for 3 days)
Study: 28419248
Drug: Everolimus 10
Normalized name: everolimus 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Everolimus 10 mg tablet orally once daily
Study: 26665291
Drug: O-R power
Normalized name: OSTOMY SET,STERILE O.R.GUARDIAN H#4673
Approvals — FDA: no, EMA: no, PMDA: no
Description: O-R power toothbrush (Oral-B Professional Care 1000 with CrossAction brush head)
Study: 23890405
Drug: Adjuvanted seasonal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvanted seasonal influenza vaccine formulations (AS03(A), AS03(B), AS03(C) with varying tocopherol and MPL doses)
Study: 23890405
Drug: Adjuvanted seasonal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvanted seasonal influenza vaccine
Study: 17544886
Drug: Enoximone (0.35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoximone (0.35 mg/kg bolus; 0.15 mg/kg before aortic cross-clamping and 0.2 mg/kg in cardioplegic solution)
Study: 2527401
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg clodronate infused intravenously daily for 10 days
Study: 2527401
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of 300 mg clodronate dissolved in 500 ml saline for 2 weeks
Study: 2527401
Drug: 500 ml
Normalized name: TPN Bag 500 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 ml saline (control) for 2 weeks
Study: 2527401
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of 1200 mg clodronate for 2 weeks
Study: 2527401
Drug: Intramuscular administration
Normalized name: Japanese Encephalitis vaccine for intramuscular administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular administration of 100 mg clodronate for 2 weeks
Study: 2527401
Drug: Maintenance therapy
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance therapy with 1200 mg clodronate/day for at least 6 weeks after a 2-week intravenous treatment course
Study: 2527401
Drug: Routine biochemical
Normalized name: Peace Out Acne Hero Routine KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine biochemical examination during and after treatment
Study: 22005142
Drug: Videoconferencing interviews
Approvals — FDA: no, EMA: no, PMDA: no
Description: Videoconferencing interviews for medication therapy management (MTM) services
Study: 19277992
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (22 mg Zn d(‐1) as zinc gluconate)
Study: 8736322
Drug: Beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate at 1 microgram/ml
Study: 8736322
Drug: Beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate at 10 micrograms/ml
Study: 8736322
Drug: Beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate at 100 micrograms/ml
Study: 2037387
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 5-FU and PP over protein-A sepharose (group A)
Study: 7247172
Drug: Intravenous succinylcholine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous succinylcholine
Study: 7247172
Drug: Intramuscular succinylcholine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular succinylcholine
Study: 30625372
Drug: Combination (strength
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination (strength + aerobic) training
Study: 28489464
Drug: Medical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical treatment continued (control group)
Study: 24732784
Drug: Resistance training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resistance training twice a week (G2)
Study: 22013957
Drug: Group-G: snack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group-G: snack fortified with G-FOS (8 g)
Study: 22013957
Drug: Group-P: fermented-malted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group-P: fermented-malted finger-millet pancake with soy coconut dip (534 mg calcium/serving)
Study: 22013957
Drug: Group-C: low
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group-C: low calcium rice-flakes snack with calcium carbonate (540 mg)
Study: 20215461
Drug: Exenatide once
Normalized name: Exenatide
DrugBank: Exenatide (DB01276)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exenatide once weekly (QW; 2 mg)
Study: 20215461
Drug: Exenatide once
Normalized name: Exenatide
DrugBank: Exenatide (DB01276)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exenatide once weekly (QW; 2 mg) after switching from exenatide BID
Study: 18410607
Drug: Ultraflex stent
Normalized name: castor fiber scent gland secretion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultraflex stent with proton pump inhibitors (n = 26)
Study: 12430779
Drug: Vitamin supplementation
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin supplementation (0.6 mg folic acid, 0.8 mg B12, and 2.0 mg B6) for 8 weeks
Study: 1330574
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg enalapril + 25 mg hydrochlorothiazide
Study: 3918684
Drug: Long term
Normalized name: BENZETHONIUM CHLORIDE 0.12 g in 100 mL TOPICAL SOLUTION [CA-REZZ - LONG TERM CARE - INCONTINENT CLEANSER]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long term hormone replacement (Mestranol)
Study: 31740866
Drug: 90% collagenated
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90% collagenated bone mix + 10% collagen gel (Group B)
Study: 26999985
Drug: MDT‐MB with
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDT‐MB with prednisolone 20 mg/day for 6 months followed by tapering by 5 mg/2 weeks in 7th and 8th month (Group A)
Study: 20932069
Drug: Intramuscular clodronic
Normalized name: Clodronic acid
DrugBank: Clodronic acid (DB00720)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular clodronic acid 100 mg once weekly (group A)
Study: 20932069
Drug: Intramuscular clodronic
Normalized name: Clodronic acid
DrugBank: Clodronic acid (DB00720)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular clodronic acid 200 mg every 2 weeks (group B)
Study: 17566842
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy combined with hyperthermia (RT + HT)
Study: 17566842
Drug: Standard radiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard radiation therapy alone (RT)
Study: 11317959
Drug: Sequential examinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential examinations for unclassifiable MPDs
Study: 8981554
Drug: Gallopamil (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gallopamil (50 mg)
Study: 27418968
Drug: MDCO-216 (ApoA-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDCO-216 (ApoA-1 Milano/POPC) infusion at doses ranging from 5 to 40 mg/kg
Study: 24755132
Drug: AMOXIL® (reference
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMOXIL® (reference formulation)
Study: 24755132
Drug: AMOXI‐PED® (test
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMOXI‐PED® (test formulation)
Study: 19033002
Drug: Higher loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher loading and initial maintenance dose of clopidogrel (600 mg loading dose on day 1 followed by 150 mg once daily on days 2 to 7, followed by 75 mg once daily on days 8-30)
Study: 19033002
Drug: High-dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose ASA (300-325 mg daily)
Study: 19033002
Drug: Standard-dose regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose regimen of clopidogrel (300 mg loading dose on day 1, followed by 75 mg once daily on days 2-30)
Study: 19033002
Drug: Low-dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose ASA (75-100 mg daily)
Study: 19033002
Drug: Higher loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher loading and initial maintenance dose of clopidogrel
Study: 24444781
Drug: High-dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose ASA
Study: 19033002
Drug: Standard-dose regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose regimen of clopidogrel
Study: 24444781
Drug: Low-dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose ASA
Study: 14568740
Drug: Neutralising antibodies
Normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neutralising antibodies positive periods
Study: 14568740
Drug: Neutralising antibodies
Normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neutralising antibodies negative periods
Study: 14568740
Drug: Antibody-negative at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibody-negative at 12 months
Study: 14568740
Drug: Presence of
Normalized name: Dna Plasmid Expressing Diphtheria Toxin Triggered By The Presence Of Oncofetal Gene H19
DrugBank: Inodiftagene vixteplasmid (DB16017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Presence of neutralising antibodies
Study: 9367476
Drug: 10 ppm
Normalized name: Glycerin 1.0 g in 25 mL TOPICAL CREAM [EGF Crystal 10 ppm]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 ppm inhaled nitric oxide (after 24 h of conventional therapy)
Study: 9367476
Drug: 10 ppm
Normalized name: Glycerin 1.0 g in 25 mL TOPICAL CREAM [EGF Crystal 10 ppm]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 ppm inhaled nitric oxide (initial treatment)
Study: 27632909
Drug: 90 g
Normalized name: Fora G90 Glucose Test Strip
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90 g of salmon twice weekly
Study: 27632909
Drug: 180 g
Normalized name: GLYCERIN 9 mg in 180 g / PANTHENOL 7 mg in 180 g CUTANEOUS FILM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 180 g of salmon twice weekly
Study: 27632909
Drug: 270 g
Normalized name: G 207
DrugBank: G207 (DB05827)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 270 g of salmon twice weekly
Study: 23921761
Drug: IV CITX
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV CITX (5‐fluorouracil 500 mg/m(2) weekly for 24 weeks, mitomycin‐C 8 mg/m(2) every 6 weeks × 4)
Study: 23921761
Drug: PO CITX
Approvals — FDA: no, EMA: no, PMDA: no
Description: PO CITX (uracil-ftorafur (UFT) 400‐600 mg/day for 12 months)
Study: 20533217
Drug: Complex micronutrient
Normalized name: hesperidin complex
DrugBank: Citrus bioflavonoids (DB14586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complex micronutrient supplement
Study: 15250846
Drug: Fibre-containing sip
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibre-containing sip feed (150 kcal, 2.0 g fibre per 100 ml)
Study: 8379600
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with zidovudine and didanosine
Study: 8379600
Drug: Zidovudine alone
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zidovudine alone (600 mg/d)
Study: 8379600
Drug: Combination regimens
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination regimens using the same zidovudine dose
Study: 26803356
Drug: Recombinant regular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant regular human insulin (RHI)
Study: 24895799
Drug: Daikenchuto (DKT),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daikenchuto (DKT), 7.5 g/day, p.o.
Study: 24895799
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (lactobacillus preparation, 3g/day, p.o.)
Study: 20697547
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy regimens including oxaliplatin, irinotecan, and 5-Fluorouracil (5-FU)
Study: 15884029
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of relaxation and chosen music
Study: 12822543
Drug: Placebo (0.9%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0.9% NaCl solution) bronchial challenge
Study: 6356899
Drug: Labetalol (median
Approvals — FDA: no, EMA: no, PMDA: no
Description: Labetalol (median daily doses of 600 mg)
Study: 30739001
Drug: 12‐month Peer‐Led,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12‐month Peer‐Led, Empowerment‐based Approach to Self‐management Efforts in Diabetes (PLEASED) program with 12 weekly contacts in the first 3 months and 18 biweekly contacts over the last 9 months.
Study: 28361739
Drug: MCT high
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: MCT high (>6 g/day)
Study: 28361739
Drug: MCT moderate
Normalized name: MCT
DrugBank: Medium-chain triglycerides (DB13959)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MCT moderate (1-6 g/day)
Study: 28361739
Drug: MCT low
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: MCT low (<1 g/day)
Study: 26518479
Drug: Intravenous ω‐3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ω‐3 PUFA‐enriched lipid emulsion 20% infusion 7 mL/kg once a day for 2 days before surgery and postoperative day (POD) 0
Study: 25003731
Drug: Oral presentation
Normalized name: Gas-X Prevention Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral presentation without demonstration
Study: 22661450
Drug: Proadrenomedullin (ProADM)
Normalized name: Adrenomedullin
DrugBank: Adrenomedullin (DB19102)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proadrenomedullin (ProADM) value ≥ 1.8 nmol/L or assignment to REA-ICU risk classes III-IV
Study: 16679997
Drug: Carbohydrate (6%)
Normalized name: pyrrolidone carboxylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate (6%) supplementation (4 mL x kg(‐1) x 15 min(‐1))
Study: 11683688
Drug: 6 mg
Normalized name: boron 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg oral tegaserod
Study: 11683688
Drug: 0.6 mg
Normalized name: thymol 0.6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.6 mg intravenous tegaserod
Study: 11683688
Drug: Oral and
Normalized name: Tridate, oral and rectal kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral and intravenous tegaserod
Study: 7713201
Drug: 1.6 mg
Normalized name: menthol 1.6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.6 mg beclomethasone dipropionate (BDP)
Study: 7713201
Drug: 2.0 mg
Normalized name: LORAZEPAM 2.0 mg in 1 mL INTRAVENOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.0 mg fluticasone propionate (FP)
Study: 23238388
Drug: Topical vitamin
Normalized name: vitamin A Topical Lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical vitamin K1 cream
Study: 23238388
Drug: Historical control
Normalized name: typhus, historical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Historical control (no vitamin K1 cream)
Study: 21497108
Drug: Left single-lung
Normalized name: beef lung preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Left single-lung transplantation (L-SLTx)
Study: 21497108
Drug: Both L-SLTx
Normalized name: L-377202
DrugBank: L-377202 (DB19022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both L-SLTx and R-SLTx
Study: 15339999
Drug: Intravenous ascorbic
Normalized name: ascorbate
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ascorbic acid (IVAA) 2000 mg
Study: 11228382
Drug: Vaccine diluent
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine diluent
Study: 1092210
Drug: Alupent Syrup
Normalized name: metaproterenol sulfate Oral Tablet [Alupent]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alupent Syrup (metaproterenol sulfate)
Study: 23150709
Drug: Chemotherapy including
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Chemotherapy including bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (6-8 cycles)
Study: 22066973
Drug: 0.125% ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.125% ropivacaine plus tramadol 5 mg/mL
Study: 22066973
Drug: 0.125% ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.125% ropivacaine plus fentanyl 3 ug/mL
Study: 11524468
Drug: Donepezil 10
Normalized name: donepezil 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donepezil 10 mg/day after initial 5 mg/day for 28 days
Study: 9252712
Drug: Maintenance endocrine
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance endocrine therapy (MET)
Study: 9252712
Drug: Epirubicin (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epirubicin (120 mg/sqm) +/− lonidamine (600 mg/daily)
Study: 8325946
Drug: Thyroxine (T4)
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Thyroxine (T4) 180 micrograms daily for 3 weeks, then 360 micrograms daily for 3 weeks
Study: 8325946
Drug: 3,5,3'-triiodothyroacetic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3,5,3'-triiodothyroacetic acid (Triac) 1700 micrograms daily for 3 weeks, then 3400 micrograms daily for 3 weeks
Study: 2942494
Drug: Midazolam 30
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam 30 mg
Study: 29998439
Drug: Ropren (polyprenol-containing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropren (polyprenol-containing drug)
Study: 24839206
Drug: Rilonacept (loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rilonacept (loading dose 4.4 mg/kg followed by 2.2 mg/kg weekly, subcutaneously)
Study: 21929831
Drug: Telephone cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telephone cognitive behaviour therapy (CBT)